JP2019529416A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529416A5
JP2019529416A5 JP2019514735A JP2019514735A JP2019529416A5 JP 2019529416 A5 JP2019529416 A5 JP 2019529416A5 JP 2019514735 A JP2019514735 A JP 2019514735A JP 2019514735 A JP2019514735 A JP 2019514735A JP 2019529416 A5 JP2019529416 A5 JP 2019529416A5
Authority
JP
Japan
Prior art keywords
klrg1
antibody
composition according
depleting agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051776 external-priority patent/WO2018053264A2/en
Publication of JP2019529416A publication Critical patent/JP2019529416A/ja
Publication of JP2019529416A5 publication Critical patent/JP2019529416A5/ja
Pending legal-status Critical Current

Links

JP2019514735A 2016-09-16 2017-09-15 Ｋｌｒｇ１枯渇療法 Pending JP2019529416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395551P 2016-09-16 2016-09-16
US62/395,551 2016-09-16
PCT/US2017/051776 WO2018053264A2 (en) 2016-09-16 2017-09-15 Klrg1 depletion therapy

Publications (2)

Publication Number Publication Date
JP2019529416A JP2019529416A (ja) 2019-10-17
JP2019529416A5 true JP2019529416A5 (https=) 2020-09-17

Family

ID=61619243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514735A Pending JP2019529416A (ja) 2016-09-16 2017-09-15 Ｋｌｒｇ１枯渇療法

Country Status (7)

Country Link
US (1) US20190194333A1 (https=)
EP (1) EP3512553A4 (https=)
JP (1) JP2019529416A (https=)
CN (1) CN110300598A (https=)
AU (1) AU2017326003A1 (https=)
CA (1) CA3036835A1 (https=)
WO (1) WO2018053264A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210002373A1 (en) * 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
WO2020060781A1 (en) * 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
EP3952999A4 (en) 2019-04-09 2023-01-25 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
CN113058029A (zh) * 2021-03-18 2021-07-02 西安交通大学 胶原凝集素-11在制备防治泌尿系统感染的药物中的应用
MX2024001277A (es) 2021-07-26 2024-02-15 Abcuro Inc Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1).
AU2023367648A1 (en) * 2022-10-25 2025-05-01 The Brigham And Women's Hospital, Inc. Klrb1 binding agents and methods of use thereof
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)
WO2026072990A1 (en) 2024-09-27 2026-04-02 Abcuro, Inc. Methods of treating t-cell large granular lymphocytic leukemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US8637084B2 (en) * 2009-07-14 2014-01-28 Asahi Kasei Medical Co., Ltd. Treatment method for epithelial cancerous organism
JP2012025694A (ja) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd 癌治療剤
MX377858B (es) * 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
WO2016013672A1 (ja) * 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
WO2017210523A1 (en) * 2016-06-03 2017-12-07 The Brigham And Women's Hospital Klrg1 signaling therapy

Similar Documents

Publication Publication Date Title
JP2019529416A5 (https=)
Wei et al. Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Claus et al. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
ES3053745T3 (en) Neutralization of inhibitory pathways in lymphocytes
US10688180B2 (en) Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
KR102787984B1 (ko) 항-lag3 항체 및 그 사용
CA2887027C (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
US20170015758A1 (en) Compositions And Methods For Modulating And Redirecting Immune Responses
CN113164598A (zh) 双特异性抗cd28 x抗cd22抗体以及其用途
JP6715491B2 (ja) 免疫チェックポイント制御剤の副作用低減方法
JP7170331B2 (ja) 固形及び血液癌の治療のための併用療法
JP2020522495A (ja) 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
EP3694552A1 (en) Anti-lap antibodies and uses thereof
US20190309066A1 (en) Combination therapy for the treatment of solid and hematological cancers
US20160257750A1 (en) Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
JP2021520201A5 (https=)
CN112292399A (zh) 抗cd27抗体及其用途
CN114206919A (zh) 靶向taci的抗体和嵌合抗原受体
WO2021080920A2 (en) Combination therapy for the treatment of solid and hematological cancers
US20230183342A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
JP2025063054A (ja) ガンマデルタｔ細胞集団の選択的生体内増殖方法及びその組成物
JP2024097985A (ja) 抗ｇｉｔｒ抗体およびその使用
EP3765519B1 (en) Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
WO2021263085A2 (en) Combination therapy for the treatment of solid and hematological cancers
Theofilidis The Goldilocks Zone: Optimizing T Cell Engager Affinity, Kinetics and Architecture for Anti-Tumor Efficacy